GENE.DH
GENE.DH's capital structure is characterized by a high debt-to-equity ratio of 1.43, indicating a significant reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.63, suggesting limited short-term liquidity to cover immediate liabilities. Despite a cash and equivalents balance of BDT 78.99 million, the company's long-term debt of BDT 3.73 billion creates a net cash negative position, raising concerns about long-term solvency. In terms of profitability, GENE.DH's return on equity (ROE) of 9.96% and return on assets (ROA) of 3.95% are below the industry median for IT Services & Consulting, indicating suboptimal capital efficiency and asset utilization. The company's operating margin of 16.6% (calculated from operating income of BDT 317.64 million on revenue of BDT 1.91 billion) is also below the industry average, suggesting room for improvement in cost management and pricing power. The company's revenue is concentrated in a single business segment, IT Services, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic downturns and regulatory shifts. The absence of segment-specific revenue breakdowns in the financial data limits the ability to assess the performance of individual business lines. GENE.DH's growth trajectory is constrained by negative free cash flow of BDT -143.54 million and capital expenditures of BDT -862.21 million, indicating that the company is investing heavily in infrastructure but not generating sufficient cash to fund these investments. The outlook for the current fiscal year shows a modest revenue increase, but the next fiscal year is expected to see a decline, reflecting potential market saturation or operational inefficiencies. The risk assessment highlights liquidity as a medium concern, with the company's net cash position being negative after accounting for total debt. The dilution risk is assessed as low, with no significant dilution events reported in the recent financial data. However, the company's reliance on debt financing and negative free cash flow could lead to future dilution if additional capital is required. Recent filings and transcripts do not indicate any major strategic shifts or new product launches. The company's focus remains on expanding its IT services portfolio and improving operational efficiency. No significant regulatory changes or geopolitical events are currently impacting the company's operations.
Business. GENE.DH provides IT services and consulting solutions, generating revenue primarily through service contracts and project-based engagements.
Classification. GENE.DH is classified under the Technology sector, specifically in the Software & IT Services business sector, with a confidence level of 0.92.
- GENE.DH has a high debt-to-equity ratio of 1.43, indicating a heavy reliance on debt financing.
- The company's ROE of 9.96% and ROA of 3.95% are below the industry median, suggesting suboptimal capital efficiency.
- GENE.DH's liquidity position is medium, with a current ratio of 0.63 and a net cash negative position.
- The company's free cash flow is negative, and capital expenditures are high, indicating significant investment in infrastructure.
- Revenue is concentrated in a single business segment, increasing exposure to regional economic downturns.
- The company's growth trajectory is constrained, with a modest revenue increase expected in the current fiscal year and a decline in the next fiscal year.
- Net cash is negative after subtracting total debt.